Summary: The GOLD Report 2021 presents new additional data on the pathogenesis of COPD. In addition, recently published data pointing to the synergistic importance of risk factors such as childhood infections and housing overcrowding were taken into account. iGCS/LABA improve the pulmonary function parameters, reduce the number of exacerbations in the group of patients with a history of exacerbations and in the group of moderate to severe COPD. iGCS/LABA/LAMA triple inhalation therapy improves lung function, reduces the severity of disease symptoms and improves patients' overall health, and has the potential to reduce the risk of exacerbations compared to iGCS/LABA, LABA/LAMA or LAMA. Today we have significant evidence that GCS can protect against COPD exacerbations in the group of patients with exacerbations and should not be discontinued in the time of the COVID-19 pandemic. GOLD 2021 recommends maintaining the current treatment (oral and inhalation) in accordance with the generally applicable principles of treating patients with COPD. The strategy for managing COPD has also been modified to include comorbid disease monitoring, vaccination, and other differential diagnosis and education activities. The tables regarding differential diagnosis of COPD exacerbations have also been modified. The patient requires holistic Doctor care.